Theralase Technologies Inc. (CVE:TLT – Get Free Report) fell 16.2% during mid-day trading on Monday . The stock traded as low as C$0.15 and last traded at C$0.16. 1,532,630 shares traded hands during trading, an increase of 1,364% from the average session volume of 104,664 shares. The stock had previously closed at C$0.19.
Theralase Technologies Stock Performance
The firm has a market capitalization of C$39.84 million, a price-to-earnings ratio of -8.61 and a beta of -0.22. The company has a 50-day moving average price of C$0.20 and a 200-day moving average price of C$0.20. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
See Also
- Five stocks we like better than Theralase Technologies
- With Risk Tolerance, One Size Does Not Fit All
- D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
- How to Profit From Value Investing
- Hims, Block, and NRG Just Launched Huge Stock Buybacks
- How to Plot Fibonacci Price Inflection Levels
- Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
